Previous findings have shown that donepezil modulates clinical symptoms in AD patients from different perspectives, such as hippocampal volume, frontal functional networks and MAPK/NLRP3 inflammasome/STAT3 signaling (Dubois et al., 2015; Griffanti et al., 2016; Kim et al., 2021). Here, NLRP3 is linked to Alzheimer disease.